Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

被引：0
|
作者：
C. Hage
V. Rausch
N. Giese
T. Giese
F. Schönsiegel
S. Labsch
C. Nwaeburu
J. Mattern
J. Gladkich
I. Herr
机构：
[1] University Clinic of Heidelberg,Section Surgical Research, Molecular OncoSurgery
[2] University of Heidelberg,Department of General Surgery, Institute for Immunology
[3] University of Heidelberg,Department of Molecular Immunodiagnostics, Institute for Immunology
来源：
Cell Death & Disease | / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
    Hage, C.
    Rausch, V.
    Giese, N.
    Giese, T.
    Schoensiegel, F.
    Labsch, S.
    Nwaeburu, C.
    Mattern, J.
    Gladkich, J.
    Herr, I.
    CELL DEATH & DISEASE, 2013, 4 : e627 - e627
  • [2] The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
    C Hage
    V Rausch
    N Giese
    T Giese
    F Schönsiegel
    S Labsch
    C Nwaeburu
    J Mattern
    J Gladkich
    I Herr
    Cell Death & Disease, 2013, 4 : e627 - e627
  • [3] The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer (vol 4, e627, 2013)
    Hage, C.
    Rausch, V.
    Giese, N.
    Giese, T.
    Schoensiegel, F.
    Labsch, S.
    Nwaeburu, C.
    Mattern, J.
    Gladkich, J.
    Herr, I.
    CELL DEATH & DISEASE, 2024, 15 (01)
  • [4] Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
    Sun, Yinggang
    Sun, Liyong
    An, Yanxin
    Shen, Xin
    MEDICAL SCIENCE MONITOR, 2015, 21 : 2316 - 2321
  • [5] c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer
    Noguchi, Kozo
    Konno, Masamitsu
    Eguchi, Hidetoshi
    Kawamoto, Koichi
    Mukai, Ryouta
    Nishida, Naohiro
    Koseki, Jun
    Wada, Hiroshi
    Akita, Hirofumi
    Satoh, Taroh
    Marubashi, Shigeru
    Nagano, Hiroaki
    Doki, Yuichiro
    Mori, Masaki
    Ishii, Hideshi
    ONCOLOGY LETTERS, 2018, 16 (02) : 1892 - 1898
  • [6] A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
    Hee Seung Lee
    Soo Been Park
    Sun A Kim
    Sool Ki Kwon
    Hyunju Cha
    Do Young Lee
    Seonggu Ro
    Joong Myung Cho
    Si Young Song
    Scientific Reports, 7
  • [7] A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
    Lee, Hee Seung
    Park, Soo Been
    Kim, Sun A.
    Kwon, Sool Ki
    Cha, Hyunju
    Lee, Do Young
    Ro, Seonggu
    Cho, Joong Myung
    Song, Si Young
    SCIENTIFIC REPORTS, 2017, 7
  • [8] Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
    Huang, Keqiang
    Liu, Dongxu
    ONCOTARGETS AND THERAPY, 2018, 11 : 5499 - 5508
  • [9] c-Met: a New Cancer Stem Cell Marker and Therapeutic Target for Pancreatic Cancer
    Wu, J-J.
    Li, C.
    Hynes, M.
    Dosch, J.
    Sarkar, B.
    Magliano, M. P.
    Simeone, D. M.
    PANCREAS, 2011, 40 (08) : 1363 - 1363
  • [10] Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer
    Vahabi, Mahrou
    Xu, Geng
    Avan, Amir
    Peters, Godefridus J.
    Giovannetti, Elisa
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2024, 43 (08): : 837 - 850
12345